Correlation Between Legend Biotech and Inhibikase Therapeutics
Can any of the company-specific risk be diversified away by investing in both Legend Biotech and Inhibikase Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining Legend Biotech and Inhibikase Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between Legend Biotech Corp and Inhibikase Therapeutics, you can compare the effects of market volatilities on Legend Biotech and Inhibikase Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in Legend Biotech with a short position of Inhibikase Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of Legend Biotech and Inhibikase Therapeutics.
Diversification Opportunities for Legend Biotech and Inhibikase Therapeutics
-0.7 | Correlation Coefficient |
Excellent diversification
The 3 months correlation between Legend and Inhibikase is -0.7. Overlapping area represents the amount of risk that can be diversified away by holding Legend Biotech Corp and Inhibikase Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Inhibikase Therapeutics and Legend Biotech is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on Legend Biotech Corp are associated (or correlated) with Inhibikase Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Inhibikase Therapeutics has no effect on the direction of Legend Biotech i.e., Legend Biotech and Inhibikase Therapeutics go up and down completely randomly.
Pair Corralation between Legend Biotech and Inhibikase Therapeutics
Given the investment horizon of 90 days Legend Biotech is expected to generate 76.97 times less return on investment than Inhibikase Therapeutics. But when comparing it to its historical volatility, Legend Biotech Corp is 2.51 times less risky than Inhibikase Therapeutics. It trades about 0.0 of its potential returns per unit of risk. Inhibikase Therapeutics is currently generating about 0.07 of returns per unit of risk over similar time horizon. If you would invest 261.00 in Inhibikase Therapeutics on September 4, 2024 and sell it today you would earn a total of 15.00 from holding Inhibikase Therapeutics or generate 5.75% return on investment over 90 days.
| Time Period | 3 Months [change] |
| Direction | Moves Against |
| Strength | Weak |
| Accuracy | 100.0% |
| Values | Daily Returns |
Legend Biotech Corp vs. Inhibikase Therapeutics
Performance |
| Timeline |
| Legend Biotech Corp |
| Inhibikase Therapeutics |
Legend Biotech and Inhibikase Therapeutics Volatility Contrast
Predicted Return Density |
| Returns |
Pair Trading with Legend Biotech and Inhibikase Therapeutics
The main advantage of trading using opposite Legend Biotech and Inhibikase Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if Legend Biotech position performs unexpectedly, Inhibikase Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Inhibikase Therapeutics will offset losses from the drop in Inhibikase Therapeutics' long position.| Legend Biotech vs. Vaxcyte | Legend Biotech vs. Apellis Pharmaceuticals | Legend Biotech vs. Travere Therapeutics | Legend Biotech vs. Akero Therapeutics |
| Inhibikase Therapeutics vs. Candel Therapeutics | Inhibikase Therapeutics vs. Cingulate Warrants | Inhibikase Therapeutics vs. Unicycive Therapeutics | Inhibikase Therapeutics vs. Cardio Diagnostics Holdings |
Check out your portfolio center.Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Transaction History module to view history of all your transactions and understand their impact on performance.
Other Complementary Tools
| Instant Ratings Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Pattern Recognition Use different Pattern Recognition models to time the market across multiple global exchanges | |
| Pair Correlation Compare performance and examine fundamental relationship between any two equity instruments | |
| Equity Analysis Research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities |